Lannett Ranitidine Syrup (Ranitidine Oral Solution, USP), 15mg/mL Rx Only Distributed by: Lannet...
FDA Drug Recall #D-0309-2020 — Class II — October 28, 2019
Recall Summary
| Recall Number | D-0309-2020 |
| Classification | Class II — Moderate risk |
| Date Initiated | October 28, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Lannett Company, Inc. |
| Location | Philadelphia, PA |
| Product Type | Drugs |
| Quantity | 683,149 bottles |
Product Description
Lannett Ranitidine Syrup (Ranitidine Oral Solution, USP), 15mg/mL Rx Only Distributed by: Lannett Company, Inc. Philadelphia, PA 19154 NDC 54838-550-80
Reason for Recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Distribution Pattern
Nationwide
Lot / Code Information
1503A 10/2019 1504A 10/2019 1505A 10/2019 1523A 10/2019 1524A 10/2019 1525A 11/2019 1561A 12/2019 1562A 12/2019 1563A 12/2019 1589A 12/2019 1590A 12/2019 1591A 12/2019 1614A 01/2020 1615A 01/2020 1617A 01/2020 1644A 02/2020 1775A 06/2020 1646A 02/2020 1647A 02/2020 1668A 03/2020 1669A 03/2020 1670A 03/2020 1708A 03/2020 1709A 04/2020 1710A 04/2020 1729A 04/2020 1730A 04/2020 1731A 04/2020 1757A 05/2020 1758A 05/2020 1759A 05/2020 1773A 06/2020 1774A 06/2020 1989A 12/2020 1794A 06/2020 1795A 06/2020 1796A 06/2020 1817A 06/2020 1818A 07/2020 1819A 07/2020 1840A 08/2020 1840B 08/2020 1841A 08/2020 1842A 08/2020 1863A 08/2020 1864A 09/2020 1865A 09/2020 1899A 10/2020 1900A 10/2020 1901A 10/2020 1910A 10/2020 1911A 10/2020 1912A 10/2020 1918A 10/2020 1919A 10/2020 1920A 10/2020 1925A 10/2020 1926A 10/2020 1927A 10/2020 1977A 12/2020 1978A 12/2020 1979A 12/2020 1990A 12/2020 1991A 12/2020 1998A 01/2021 1999A 01/2021 2000A 01/2021 2019A 01/2021 2020A 01/2021 2065A 03/2021 2066A 03/2021 2067A 03/2021 2071A 03/2021 2072A 03/2021 2073A 03/2021 2076A 03/2021 2077A 03/2021 2078A 03/2021 2126A 05/2021 2127A 05/2021 2128A 05/2021 2164A 06/2021 2165A 06/2021 2166A 06/2021 2179A 06/2021 2180A 07/2021 2181A 07/2021 2214A 08/2021 2215A 08/2021 2216A 08/2021
Other Recalls from Lannett Company, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0558-2022 | Class II | Diazepam Oral Solution (Concentrate), 25 mg per... | Feb 9, 2022 |
| D-1508-2020 | Class II | Prednisone Tablets, USP 2.5 mg, 100 tablets, Rx... | Aug 10, 2020 |
| D-0630-2020 | Class I | Levetiracetam Oral Solution 100mg/mL, 473 mL (1... | Dec 6, 2019 |
| D-0083-2019 | Class II | HydrOXYzine HYDROCHLORIDE SYRUP (HydrOXYzine Hy... | Oct 11, 2018 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.